An observational study in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.
Sponsored by King's College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom — 20 open to participants now, 28 under way, 6 of them phase 3. Inflammatory Bowel Diseases · United Kingdom.
Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, this one is the 25th largest by planned enrollment of the 42 observational ones that give a count, is one of 5 that started in 2023, is one of 42 observational ones, reaches primary completion later than 5 of the 27 other live ones, and was the 98th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →20 of the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
Janssen-Cilag Ltd. · Sites in United Kingdom
Ages 18+
Nutricia UK Ltd · Sites in United Kingdom
Ages 3+
Barts & The London NHS Trust · Sites in United Kingdom
Ages 16+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 22 · Phase 4 4
First in 2006; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 95 across the 70 interventional studies, 215 across the 42 observational. Of the 67 that completed or were terminated, 26 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 112 have an industry lead sponsor. The 10 most frequent:
King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.
King's College London has 5 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Inflammatory Bowel Diseases with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT06723418University of GlasgowDevelopment and Validation of a New Paediatric Inflammatory Bowel Disease NUTrition Risk Score (PIBD-NUTS) | 2026-12 |
| NCT06956703University of NottinghamNAZA - Nottingham/Astra ZenecA Prospective IBD Cohort Study | 2026-12-31 |
| NCT06877923Nutricia UK LtdElemental 028 Extra Case Studies | 2027-02 |
| NCT06286709University of BirminghamFAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis | 2027-09-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 112 studies in Inflammatory Bowel Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An aspect of IBD care that is often overlooked is mental health treatment. Common mental health problems, such as anxiety and depression are very common in IBD, with a meta-analysis estimating prevalence as high as 25.2% for depression and 32.1% for anxiety. The prevalence of anxiety and depression increases when individuals with active disease are considered, with rates as high as 57.6% for anxiety and 38.9% for depression. Comorbid depression and anxiety in IBD is associated with greater symptom severity, even when statistically controlling for disease activity; more frequent and expensive emergency department visits and inpatient stays, higher costs relating to IBD-related surgery, medication and personal expenditure; noncompliance with medical treatment and finally, increased likelihood of experiencing flares.
However, very few studies attempt to unpick the precise mechanism of these bidirectional relationships.
Indeed, depression and anxiety may have direct effects on physical health through inflammatory or psychoneuroimmunological pathways. Very few studies investigate the longitudinal brain-gut relationship with regards to objective measures of inflammation. Additionally, the indirect effects of mental health are often overlooked. Depression and anxiety are routinely associated with health behaviours, such as diet, physical activity, sleep, and tobacco/alcohol use.These health behaviours are important factors, given their impact on physical health outcomes. Therefore, a thorough investigation is required to ascertain the precise mechanisms that underpin the bidirectional relationship between depression/anxiety and inflammation/physical health, as this will enable practitioners and researchers to establish non-invasive, behavioural treatment targets for this patient group.
AIM The broad aim of this project is to explore whether anxiety/depression has a direct or indirect (via health behaviours) on i) inflammation levels ii) clinical activity and iii) healthcare usage at follow-up, in a population of IBD patients. A secondary aim of the project will be to explore whether changes in disease activity, as measured by self-report measures and faecal calprotectin, explains changes in anxiety and depression symptoms at follow up.
Participants will be asked to answer online questionnaires at 3 time points, 6 months apart. They will also be asked to do an at-home stool sample test at the first two time points.
Adults with IBD in the UK, who have experienced a flare within the last 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete 3 online questionnaires at 6 month intervals. At the first two time points they will also be asked to submit 2 at home stool sample tests, to assess fecal calprotectin.
Other: Data collection
Participants will answer questionnaires and submit stool samples.
Psychological distress: Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)
The PHQ-ADS is a composite measure of the Generalised Anxiety Disorder questionnaire (GAD-7) and the Patient Health Questionnaire (PHQ-9). Min score = 0, Max score = 48, with higher scores indicating higher levels of distress.
Time frame: Month 0, Month 6, Month 12
Depression: Patient Health Questionnaire - (PHQ-9)
Depression. Min score = 0, Max score = 27, with higher scores indicating greater depression.
Time frame: Month 0, Month 6, Month 12
Anxiety: Generalised Anxiety Disorder scale (GAD-7)
Anxiety. Min score = 0, Max score = 21, with higher scores indicating greater anxiety
Time frame: Month 0, Month 6, Month 12
Fecal Calprotectin
Measure of intestinal inflammation, higher levels indicate greater inflammation.
Time frame: Month 0, Month 6
Health service use
4 service use items (GP, psychologist, emergency care, secondary care service) from the client service receipt inventory (CSRI) will be used. Frequency and duration of particular services will be recorded, from which a total time will be calculated. There is no maximum value. Higher scores indicate more health service time used.
Time frame: Month 0, Month 6, Month 12
IBD activity
For Crohn's Disease patients: The Patient-Reported Outcomes for the Assessment of Crohn's Disease Activity (PRO-CD). The scale contains two sub-scales: 1) bowel signs and symptoms, 2) functional symptoms. Each scale is scored separately. There is no total score for the PRO-CD. The first sub-scale starts at 0 and has no maximum value, with greater scores indicating greater bowel signs/symptoms. The second subscale ranges from 0-21, with higher scores indicating greater functional symptoms. For Ulcerative Colitis / unclassified patients: The Patient-Reported Outcomes for Assessment of Ulcerative Colitis (PRO-UC). The scale has 9-items and includes two scales: 1) Bowel signs/symptoms and 2) functional symptoms. The first sub-scale starts at 0 and has no maximum value, with greater scores indicating greater bowel signs/symptoms. The second subscale ranges from 0-21, with higher scores indicating greater functional symptoms.
Time frame: Month 0, Month 6, Month 12
Body Mass Index
Weight (in kg) and Height (in m) will be combined to calculate BMI (weight in kg / (height in m)\^2
Time frame: Month 0, Month 6, Month 12
Smoking status
Current smoking status, including amount of cigarettes consumed per day.
Time frame: Month 0, Month 6, Month 12
Alcohol Consumption
Number of units drunk in the past week.
Time frame: Month 0, Month 6, Month 12
Physical activity: International Physical Activity Questionnaire
Physical activity. There are three subscales (vigorous activity, moderate activity and lower-level activity). Scores will be in minutes. Higher scores will indicate more physical activity performed.
Time frame: Month 0, Month 6, Month 12
IBD medication
Current medication and dose.
Time frame: Month 0, Month 6, Month 12
IBD flares
Frequency and severity (4-point scale) of IBD flares (in last 6 months)
Time frame: Month 0, Month 6, Month 12
Sleep - the Pittsburgh Sleep Quality Index (PSQI)
Sleep quality in the last month. Min=0, max=21, with higher scores indicating worse sleep quality.
Time frame: Month 0, Month 6, Month 12
Diet - Healthy Eating Assessment
8-item simplified food frequency questionnaire designed for use in primary care settings. The tool will be adapted so that each item is score 1-5. Mix=8, max=40, with higher scores indicating better diet quality.
Time frame: Month 0, Month 6, Month 12
IBD quality of life - short Inflammatory Bowel Disease Questionnaire (sIBDQ)
The sIBDQ is a ten-item questionnaire that covers four domains: bowel symptoms, systemic symptoms, emotional health, and social functions. Min=10, max=70, with a lower score indicating lower quality of life.
Time frame: Month 0, Month 6, Month 12
Medication Adherence - Medication Adherence Report Scale (MARS)
5-item scale on a 5-point scale.Mix=0, Max=20, with higher scores indicating better adherence.
Time frame: Month 0, Month 6, Month 12
Plan to share: Undecided
Started Apr 2023 (actual). Primary completion is estimated for Dec 2024, 20 months after the start.
Of 244 non-industry observational studies under Inflammatory Bowel Diseases, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 132. This study's planned 20 months is below that.
Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.